The unique life cycle of adeno-associated virus (AAV) and its ability to infect both
nondividing and dividing cells with persistent expression have made it an attractive vector …

Gene therapy vectors based on the adeno-associated virus (AAV) are being developed for a
widening variety of therapeutic applications. Enthusiasm for AAV is due, not only to the …

Adeno-associated virus (AAV) has emerged as an attractive vector for gene therapy. The
benefits of using AAV for gene therapy include long-term gene expression, the inability to …

Adeno-associated virus (AAV) based vectors have emerged as important tools for gene
therapy in humans. The recent successes seen in Phase I/II clinical trials have also …

ADENO-ASSOCIATED VIRUS (AAV) VECTORS were first devel-oped 20 years ago (Carter,
2004) and an AAV vector was first administered to a human subject in November 1995 …

The adeno-associated virus (AAV) has rapidly gained popularity in gene therapy since the
establishment of the first AAV2 infectious clone, in 1982, due to some of their distinguishing …

Adeno-associated virus (AAV) is a small, nonenveloped virus that was adapted 30 years
ago for use as a gene transfer vehicle. It is capable of transducing a wide range of species …

Fifty years after the discovery of adeno-associated virus (AAV) and more than 30 years after
the first gene transfer experiment was conducted, dozens of gene therapy clinical trials are …

The adeno-associated virus (AAV) is one of the most promising viral vectors for human gene
therapy. As with any potential therapeutic system, a thorough understanding of it at the in …

Recombinant adeno-associated virus (rAAV) vectors are unique among the vector classes
currently available for human gene therapy in that they are based upon a class of viruses …